Disease and region specificity of granulin immunopositivities in Alzheimer disease and frontotemporal lobar degeneration

Qinwen Mao*, Dongyang Wang, Yanqing Li, Missia Kohler, Jayson Wilson, Zachary Parton, Bella Shmaltsuyeva, Demirkan Gursel, Rosa Rademakers, Sandra Weintraub, Marek Marsel Mesulam, Haibin Xia, Eileen H. Bigio

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Heterozygous loss-of-function mutations in GRN, the progranulin gene, which result in progranulin (PGRN) protein haploinsufficiency, are a major cause of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). PGRN is composed of seven and a half repeats of a highly conserved granulin motif that is cleaved to produce the granulin peptides A-G and paragranulin. To better understand the role of PGRN and granulin (Grn) peptides in the pathogenesis of neurodegeneration, we evaluated PGRN/Grn in brains of patients with Alzheimer disease, FTLD-TDP type A with or without GRN mutations, and normal individuals, using a panel of monoclonal antibodies against Grn peptides A-G. In the neocortex, Grn peptide-specific immunostains were observed, for example, membranous Grn E immunopositivity in pyramidal neurons, and Grn C immunopositivity in ramified microglia. In the hippocampus, Grn immunopositivity in the CA1 and CA2 regions showed diseasespecific changes in both neurons and microglia. Most interestingly, in FTLD-TDP type A with GRN mutations, there is a 60% decrease in the density of Grn-positive microglia in the hippocampal CA1, suggesting that haploinsufficiency of the GRN mutations also extends to PGRN expression in microglia. This study provides important insights into future studies of the pathogenesis and treatment of FTLD-TDP.

Original languageEnglish (US)
Pages (from-to)957-968
Number of pages12
JournalJournal of neuropathology and experimental neurology
Volume76
Issue number11
DOIs
StatePublished - Nov 1 2017

Funding

From the Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (QM, MK, EHB); Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi’an, Shaanxi, P.R. China (DW, YL, HX); The Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (JW, ZP, SW, M-MM, EHB); Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Northwestern University School of Medicine, Chicago, Illinois (BS, DG); and Department of Neuroscience, Mayo Clinic, Jack-sonville, Florida (RR) Send correspondence to: Qinwen Mao, MD, PhD, Department of Pathology, School of Medicine, Northwestern University Feinberg, 710 N Fairbanks Ct, Olson 2-458, Chicago, IL 60611; E-mail: [email protected] This study was supported by New Faculty Startup Funds (Qinwen Mao), Alzheimer’s Disease Research Fund Grant (83282003F) from the Illinois Department of Public Health (Qinwen Mao), an Alzheimer’s Disease Core Center grant (P30 AG013854) from the National Institute on Aging to Northwestern University, Chicago Illinois, R35 NS097261, and the re-search grants from the National Natural Science Foundation of China (No. 81471772 and No. 81773265) (Haibin Xia), and the Fundamental Research Funds for the Central Universities (No. GK201706002) (Haibin Xia).

Keywords

  • Alzheimer disease
  • Frontotemporal lobar degeneration
  • Granulin
  • Hippocampal sclerosis
  • Microglia
  • Neuroinflammation
  • Progranulin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Cellular and Molecular Neuroscience
  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'Disease and region specificity of granulin immunopositivities in Alzheimer disease and frontotemporal lobar degeneration'. Together they form a unique fingerprint.

Cite this